On diabetic foot, wound healing, amputation prevention, and the merger of consumer tech with medical devices
Three new papers converge on a two-cent idea: the neutrophil percentage-to-albumin ratio (NPAR) measures the balance between inflammatory injury and nutritional reserve — tracking both how bad the diabetic foot is now and how the patient fares over years. Plus a clear-eyed look at why AI-driven precision nutrition isn't here yet, and what it will take.
Windy Cole and colleagues propose a master-protocol basket trial that borrows oncology's tissue-agnostic playbook for hard-to-heal wounds — testing a single mechanism-targeted therapy across diabetic foot and venous leg ulcers under one Bayesian, sham-controlled design. We've spent a decade framing the diabetic foot like cancer; here, the trial architecture grows up to match.
The World Cup isn't the only global tournament underway. Thanks to Anica Badanjak and Anela Novak's new Croatian translation, the IWGDF Guidelines now reach patients in a native language on every inhabited continent on Earth — every single one.
Two diabetic foot data engines published the same day on two continents. STEADY (US) is a 5,000-patient, AI-enabled real-world registry; DARE-DiaFoot (Italy) is a deep, multi-instrumental phenotyping protocol that quietly studies remission. One is the census, the other the core sample. Together with EURODIALE, the U.S. Wound Registry, and the National Diabetes Foot Care Audit, they sketch a blueprint for finally measuring what we manage.
A new paper in BMC Health Services Research describes how we co-created a Foot Selfie app with, not for, people living with diabetes, caregivers, and clinicians in urban Lima and semi-rural Piura, Peru. Here is how the end-users redesigned remote diabetic foot surveillance to fit the rooms where it actually happens.
Notes from the Beaumont Multidisciplinary Diabetic Foot Symposium in Dublin (18 June 2026) — a true toe-and-flow gathering across vascular surgery, podiatry, endocrinology and infectious diseases, where the watchword was remission, not cure.
A new multi-omics preprint uses Mendelian randomization to argue that six circulating miRNAs causally regulate peripheral artery disease in the diabetic foot—and flags metformin as the most translationally tractable repurposing candidate. A nice piece of computational scaffolding, with the usual in-silico caveats.
A new 5,698-patient real-world cohort from Valladolid (Del Río-Solá et al., Adv Wound Care 2026) reports 61.8% five-year survival overall, falling to 32.1% after major amputation — and concludes the diabetic foot ulcer should be treated as a marker of advanced systemic disease, not an isolated wound. The newest entry in a fifteen-year line of evidence putting DFU mortality squarely in the cancer conversation.
A new Queensland study from Son Nghiem, Pete Lazzarini, Lauren Ward and colleagues in Diabetic Medicine finds that investing in earlier access to diabetic foot services returns nearly $8 for every $1 spent — with lower costs, fewer hospitalisations, and better quality of life.
We moved to the toe pressure precisely because digital arteries were supposed to be spared from calcification. A new JVS-Vascular Insights study from Welling, Bakker, Ferraresi and colleagues finds digital artery calcification in nearly 30% of limbs, shows it doubles one-year limb-event risk, and that it falsely elevates toe pressure — with a simple fix: when calcium shows on the foot film, subtract 20–30 mmHg.
